SC-53228

• Description :

  SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis[1][2].

• CAS Number :

  [153633-01-3]

• UNSPSC :

  12352005

• Target :

  Leukotriene Receptor

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Smiles :

  CCCC1=C2C(CC[C@H](O2)CCC(O)=O)=CC=C1OCCCOC3=C(C(OC)=C(C=C3)C(NC)=O)CC4CC4

• Molecular Formula :

  C31H41NO7

• Molecular Weight :

  539.66

• References & Citations :

  [1]Fretland DJ, et al. Dermal inflammation in primates, mice, and guinea pigs: attenuation by second-generation leukotriene B4 receptor antagonist, SC-53228. Inflammation. 1995 Jun;19 (3) :333-46. |[2]Fretland D, et al. Oral efficacy of a leukotriene B4 receptor antagonist in colitic cotton-top tamarins. Gut. 1995 Nov;37 (5) :702-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported